2017-10-25 20:10:38 UTC

Can You Explain Biosimilars to Patients?

Oct. 25, 2017

AGA is taking the lead in educating health care professionals and their patients about biosimilars and how they can play a role in IBD patient care.

The advent of biosimilars has helped propel the future of inflammatory bowel disease (IBD) treatment and care. While they expand treatment options, they also raise a lot of questions. AGA has created educational resources answering common questions pertaining to biosimilars for both patients and physicians.

New guides support shared-decision making practices for IBD treatment discussions on biologics and biosimilars, helping to ensure that everyone involved in IBD care can come to the table equipped with the knowledge to make the right, informed choice for treatment.

Interactive patient guide on biologic and biosimilar drugs — reviews common questions patients should know about biosimilar drugs. Included in the guide are downloadable resources, such as medication logs and questions for doctors, videos and quizzes to capture knowledge gained. Requests for reprints are offered at no cost to AGA members.  

Physician pocket guide on understanding biologics and biosimilars — provides need-to-know information about the development of biosimilar drugs and how to prepare for discussions with IBD patients.

The guides were developed with support by an educational grant from Amgen.

Additional resources on biosimilars are also available.

For additional IBD and other patient education resources, free to members, visit the AGA Patient Info Center. This digital library covers 25 different GI topics.

More on Biosimilars

Comprehensive Update of Biosimilar Therapies: Your Questions Answered

Dec. 11, 2017

Gain a better understanding of the evidence currently available on biosimilars for IBD and how to educate/discuss biosimilars with patients.

Considerations in Use of Biosimilars for Gastrointestinal Disorders

July 19, 2017

Considerations in Use of Biosimilars for Gastrointestinal Disorders

Advent of Biosimilar Products in US GI Practice

July 19, 2017

Advent of Biosimilar Products in US GI Practice